Jiangsu Kanion Pharmaceutical Co., Ltd.

Newgen Therapeutics, Inc.

Jiangsu Kanion Pharmaceuticals, Co. Ltd.

China Railway Engineering Equipment Group Co., Ltd.

Jiangsu Kanion Parmaceutical Co. Ltd

Wei Xiao

Jian Li

Shuhui Chen

Peng Li

Zhenzhong Wang

Wang Shen

Wei Shi

Lin Feng

Hanfei Hu

Chenfeng Zhang

Haiying He

Bailing Yang

Yongxiang Wang

Xiaodong Kang

Xiujuan Chang

Enli Zhou

Yun Wu

Zheng Kuan Wang

Gang Wang

Jack Maung

Ning Li

Zhen Wang

Xiaoling Zheng

Weiming Chen

Jianbin Li

Aimin Zhang

Ying Zhu

Zongbin Li

Fei Hao

Lianhui Jia

Xiang Dai

Zhangjian Huang

Jiayi Zhu

Tuanjie Wang

Yingguang Li

Jianbing Wu

Yihua Zhang

Qingming Guo

Xu Li

Wei Zhang

Xueshi Huang

Shasha Gu

Guiping Li

Haibo Li

Quanchang Zhang

Liang Cao

Wenjun Liu

Kejin Zhu

Yong Zhang

Zhimin Du

Jinhui Wang

Yunlong Bai

Xin Li

Chaoqian Xu

Yanjie Lv

Ya Ling

Yu An Bi

Zeyu Cao

Baofeng Yang

Zhengkuan Wang

Ningbo Cheng

Zheng Wang

Zhen Zhong Wang

Xiang Ling Dai

Tianren Yang

Xiaolian He

Xuehong Dong

Yanqiu Wang

Hui Zhang

Juhui Yang

Dan Lv

Qian Zhou

Yangyi Yan

Xidong Zhang

Wei Wang

Xingjian Zhuo

Dujuan Wang

Lixun Zhang

Qingzeng Yu

The disclosure relates to a traditional Chinese medicine composition, comprising active ingredients derived fromoretartifactus and Lapis Chloriti, the said active ingredients comprise in parts by weight: at least 1600 parts of amino acids; at least 120 parts of gallic acid; at least 130 parts of liquiritin; at least 20 parts of liquiritigenin; at least 400 parts of baicalin; at least 40 parts of oroxyloside; at least 120 parts of wogonoside; at least 280 parts of glycyrrhizic acid; at least 12 parts of chrysin-7-O-β-D-glucoronic acid; at least 50 parts of aloe-emodin-8-O-β-D-glucopyranoside; at least 30 parts of chrysophanol-1-O-β-D-glucopyranoside; at least 45 parts of chrysophanol-8-O-β-D-glucopyranoside; at least 260 parts of hyodeoxycholic acid; at least 150 parts of cholic acid. The traditional Chinese medicine composition in the present invention possess antipyretic, anti-inflammatory and antitussive effects.

Traditional Chinese medicine composition and use thereof

The present invention discloses a crystal form A of a compound, where the compound is S-(−)-2,3-methylenedioxy-5,8,13,13a-tetrahydro-10,11-dimethoxy-6H-dibenzo[a, g]quinolizine, and an X-ray powder diffraction pattern of the crystal form A includes three or more 2θ values selected from the group consisting of: 12.21±0.2°, 13.381±0.2°, 15.181±0.2°, 16.171±0.2°, 17.101±0.2°, 19.801±0.2°, 21.511±0.2°, 24.391±0.2°, and 25.321±0.2°. The crystal form A of the compound of the present invention does not contain water and a solvent, has high stability and low hygroscopicity, and is suitable for patent medicine.

Crystal form of compound, and preparation method therefor and use thereof

The present disclosure discloses salts formed by 2-(1-acyloxy-n-pentyl)benzoic acid and basic amino acid or aminoguanidine, a preparation method thereof, pharmaceutical preparations containing these salts, and application thereof in preparation of drugs for preventing or treating ischemic cardiovascular and cerebrovascular diseases, resisting thrombosis and improving cardio-cerebral circulation disorders. The compound of the present disclosure has excellent water solubility, aqueous solution stability and pharmacokinetic properties, also has significant anti-platelet aggregation, anti-thrombosis, anti-cerebral ischemia and neuroprotective activity. The compound of the present disclosure has significantly better effects than those of (S)-butylphthalide and potassium (R/S)-2-(1-hydroxy-n-pentyl) benzoate (PHPB), has significantly lower acute toxicity to mice by intravenous injection than that of butylphthalide and PHPB, has a lower inhibition rate of the hERG potassium channel in CHO-hERG cells than that of (S)-butylphthalide, and has a negative result in Bacterial Reverse Mutation Test (Ames test).

Salts formed by 2-(1-acyloxy-n-pentyl) benzoic acid and basic amino acid or aminoguanidine, and preparation method and application thereof

A traditional Chinese medicine composition, made from cassia twig,alba, peach kernel in equal proportions. The traditional Chinese medicine composition comprises paeoniflorin, amygdalin, benzoylpaeoniflorin, cinnamic acid, paeonol, and cinnamaldehyde. The composition has the advantages of high production efficiency, high content of effective ingredients, high transfer rate ofacid, reduced hygroscopicity, and improved dissolution of index ingredients.

Traditional Chinese medicine composition and preparation method and application thereof

Aditerpene lactone composition is provided. The extract can lower the neurological function score of a cerebral ischemia-reperfusion rat, reduce the cerebral ischemia area and the water content after brain tissue edema, improve SOD activity, and decrease the MDA content. The composition can inhibit rabbit platelet aggregation induced by PAF and ADP inducers at different time points so as to reduce the maximum aggregation rate. In addition, experiments show that the effect of each monomer compound in thediterpene lactone composition is significantly increased at certain proportion.

Gingko diterpene lactone composition

Aditerpene lactone composition is provided. The composition has the effect of improving a depressive state. The composition can prolong a tail flick interval time and a swimming interval time of a mouse to different degrees and can also increase the frequency of escaping from electric shock to different degrees. The additional addition of a certain amount of ginkgolide C, ginkgolide J, and ginkgolide L greatly enhances the effect of improving the depressive state. It is further proved through experiments that after the provision of thediterpene lactone composition, indexes, such as SOD, MDA, GSH, and TAC, can be improved to different degrees. For example, after the addition of a certain amount of ginkgolide C, ginkgolide J, and ginkgolide L, the improving effect gets more obvious, the oxidative stress level can be better improved, and the oxidative damage can be relieved.

Ginkgo diterpene lactone composition

Disclosed in the present invention are an emodin succinyl ester compound, a preparation method therefor and a use thereof, the emodin succinyl ester compound having the structure as represented by formula I (R being a Calkyl group). The method provided in the present invention has a simple method course, and may effectively save time in synthesis and reduce costs, being simple to operate, being easy to implement, and being suitable for industrial production. Experiments show that the emodin succinyl ester compound of the present invention may better promote the healing of diabetic wounds than emodin, and may be used for preparing a drug for promoting the healing of diabetic wounds. Moreover, it has been confirmed by means of performing pharmacological experiments on rats suffering from experimentally mixed hyperlipidemia that the emodin succinyl ester compound of the present invention is superior to emodin, and has the advantages of having a remarkable blood fat lowering effect, being safe, being simple and convenient to administer, the raw materials being low cost and readily available, and being easy to transport and store.

Emodin succinyl ester compound, preparation method therefor and application thereof

The present invention discloses a salt form, crystal form and intermediate of the compound 1, and preparation method thereof. 

Salt form and crystal form of 1,2,5-thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate

Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof, and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof. 

Anti-enterovirus 71 thiadiazolidine derivative

The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.

Quinazoline-7-ether compounds and methods of use

This invention provides a method for identifying a composition of Cinnamomi and Poria. This invention further provides a composition comprising: Ramulus Cinnamomi, Poria Cortex, Moutan Radicis, Radix Paeonize Alba, and Semen Persicae. This invention provides various uses of these compositions.

Cinnamomi and poria composition, method to prepare same and uses thereof

A composition comprising Chinese herbal medicinesandis provided, wherein the composition is defined by a fingerprint profile obtained from an improved chromatographic method. Various uses of such compositions are also provided.

[object Object]

This invention provides a method for identifying a composition ofand. This invention further provides a composition comprising: Ramulus Cinnamomi, Poria Cortex, Moutan Radicis, Radix Paeonize Alba, and Semen Persicae. This invention provides various uses of these compositions.

The invention discloses a medicine that can treat CRF and the preparation method of it, which mainly make up of fleece-flower root, dodder, pseudostellaria root, atractylodes rhizome, wolfberry fruit,root the invented medicine absorb quickly, have good curative effect, with high content of effective component and admit is convenience.

Herbal composition for treatment of chronic renal failure and method to produce thereof

Growing community of inventors

Jiangsu, China

Wei Xiao